Why do nrtis cause lactic acidosis

Overview

Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of antiretroviral drugs that have been fundamental to HIV treatment since the approval of zidovudine (AZT) in 1987. These drugs work by incorporating into viral DNA during reverse transcription, causing chain termination and inhibiting HIV replication. By the mid-1990s, as combination antiretroviral therapy became standard, clinicians began reporting cases of severe lactic acidosis in patients receiving NRTIs, particularly with stavudine (d4T) and didanosine (ddI). The first systematic descriptions emerged in 1994-1995, with case series documenting mortality rates exceeding 50% in severe presentations. This discovery revealed an important class-specific toxicity that has influenced drug development and clinical monitoring practices. Today, while newer NRTIs like tenofovir and emtricitabine have lower mitochondrial toxicity, understanding this mechanism remains crucial for managing patients on long-term antiretroviral therapy.

How It Works

The mechanism begins with NRTIs being phosphorylated to their active triphosphate forms within cells. While designed to inhibit HIV reverse transcriptase, these compounds also inhibit human mitochondrial DNA polymerase gamma, the enzyme responsible for mitochondrial DNA replication. This inhibition reduces mitochondrial DNA synthesis by 50-80% in affected tissues, particularly in highly metabolic organs like liver, muscle, and adipose tissue. With diminished mitochondrial DNA, cells cannot produce adequate amounts of proteins essential for the electron transport chain, impairing oxidative phosphorylation. This forces cells to rely more on anaerobic glycolysis for ATP production, generating lactate as a byproduct. The lactate accumulation, combined with reduced hepatic clearance due to mitochondrial dysfunction in liver cells, leads to systemic lactic acidosis. The severity depends on the specific NRTI's affinity for polymerase gamma, with stavudine showing the highest binding affinity among commonly used agents.

Why It Matters

Understanding NRTI-induced lactic acidosis is crucial because it represents a potentially fatal complication of essential HIV medications, with historical mortality rates reaching 33-57% in severe cases. This knowledge has driven the development of safer NRTIs with lower mitochondrial toxicity, such as tenofovir alafenamide, which has largely replaced higher-risk agents like stavudine in global HIV programs. Clinically, it necessitates regular monitoring of lactate levels and liver function in patients on NRTI-containing regimens, particularly those with risk factors like obesity or liver disease. The condition also serves as an important model for understanding drug-induced mitochondrial toxicity more broadly, with implications for cancer chemotherapy and other therapeutic areas where mitochondrial function is compromised. Early recognition and drug discontinuation can prevent progression to severe metabolic acidosis and multi-organ failure.